

**Listing of the Claims**

1.-13. (Previously cancelled)

14. (Currently amended) A compound which is 1-[2-(2-ethyl-2H-tetrazol-5-yl)-ethyl]-3-[5-(3-fluoro-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-urea in free or salt form,

15-19. (Previously cancelled)


20. (Previously amended) A pharmaceutical composition comprising a compound according to claim 14, in free or salt form.

21. (Withdrawn) A method of treating a disease mediated by phosphatidylinositol 3-kinase in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound as defined in claim 14 in free form or in the form of a pharmaceutically acceptable salt.


22. (Withdrawn) A method of treating respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity or restenosis in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound as defined in claim 14 in free form or in the form of a pharmaceutically acceptable salt.

23. (Withdrawn) A process for preparing a compound as defined in claim 14, in free or salt form which comprises the steps of:

- (i) (A) reacting a compound of formula II




wherein T is a 5- or 6-membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, with a compound of formula III




or

- (B) reacting a compound of formula IV




with a compound of formula III or

- (C) reacting a compound of formula V



with a compound of formula VI



and

- (ii) recovering the resultant compound in free or salt form.